All In Biotech

NDA 220442 · Shionogi

Xocova

Ensitrelvir · Oral

Novel

CDER novel approval, May 29, 2026: To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

May 29, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

3 Phase 3, 1 recruiting

FAERS reports

18

8 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 3, 2026.

XOCOVA is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19. XOCOVA, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro : also referred to as 3CL pro or nsp5 protease) inhibitor, is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID‑19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19. ( 1 )

Mechanism: Ensitrelvir is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 29, 2026 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • XOCOVA · ENSITRELVIR 125MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ensitrelvir" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction8
  • product use in unapproved indication7
  • drug half-life increased4
  • immunosuppressant drug level increased4
  • covid-193
  • covid-19 pneumonia3
  • drug clearance decreased3
  • blood creatinine increased2
  • drug ineffective for unapproved indication2
  • drug level increased2
  • off label use2
  • pneumonia2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20232
20248
20256
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 21 on PubMed

Sponsor: Shionogi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.